New hope for rare skin cancer: targeted antibody tested in china
NCT ID NCT06285370
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph nodes, and blood. Researchers will measure how many patients achieve a complete or partial response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mogamulizumab (a monoclonal antibody given by IV infusion)
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with these rare skin lymphomas who have not responded to prior therapies.
What could go wrong
This is a small, single-arm study with only 23 participants, so results may not apply broadly. The drug may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Zhengzhou University
Henan, Zhengzhou, 450052, China
-
Peking University First Hospital, Department of Dermatology and Venereology
Beijing, Beijing Municipality, 100034, China
-
Sun Yat-sen University Cancer Center, Department of Medical Oncology
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, 010000, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110002, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610044, China
-
ZheJiang Cancer Hospital
Hangzhou, Zhejiang, 310005, China